References
- Fisher EJ, Chaloner K, Cohn DL, Grant LB, Alston B, Brosgart CL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15: 1695–700.
- Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29: 948–9.
- Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase 1/2 trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733–9.
- Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients:results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257–63.
- Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleosideresistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139: 313–20.
- Unwin RJ, Capasso G. The renal tubular acidoses. J R Soc Med 2001; 94: 221–5.
- Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383–93.
- Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325: 349–62.
- Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses 1997; 13: 707–12.
- Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a patient with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003; 47: 262–3.
- Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342–4.
- Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17: 935–7.
- Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: 3 cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070–3.
- Murphy MD, O’Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36: 1082–5.
- Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: e41–3.
- Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331–3.
- Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002; 24: 1515–48.
- Reynes J, Peyriere H, Merle C. de Boever, Le Moing V. Renal tubular injury and severe hypophosphoraemia (Fanconi syndrome) associated with tenofovir therapy [abstract no. 717]. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14 2003, Boston, MA.
- Kearney BP, Liaw S, Yale K. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment [abstract]. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 17–21, 2002.